XBI - SPDR S&P Biotech ETF
| Assets | $6.89B |
| NAV | $128.50 |
| Expense Ratio | 0.35% |
| PE Ratio | 9.25 |
| Beta (5Y) | 1.30 |
| Dividend (ttm) | $0.32 |
| Dividend Yield | 0.25% |
| Ex-Dividend Date | Mar 22, 2021 |
| 1-Year Return | - |
| Trading Day | April 22 |
| Last Price | $135.95 |
| Previous Close | $132.77 |
| Change ($) | 3.18 |
| Change (%) | 2.40% |
| Day's Open | 132.43 |
| Day's Range | 130.81 - 136.86 |
| Day's Volume | 5,449,842 |
| 52-Week Range | 89.24 - 174.74 |
Fund Description
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI).
| Asset Class Equity | Sector Biotech |
| Region North America | Inception Date Jan 31, 2006 |
| Exchange NYSEARCA | Ticker Symbol XBI |
| Index Tracked S&P Biotechnology Select Industry Index | |
Top 10 Holdings
8.18% of assets| Name | Symbol | Weight |
|---|---|---|
| United Therapeutics | UTHR | 0.94% |
| Vericel | VCEL | 0.83% |
| Moderna | MRNA | 0.83% |
| Amgen | AMGN | 0.82% |
| MacroGenics | MGNX | 0.81% |
| Cytokinetics | CYTK | 0.80% |
| Alexion Pharmaceuticals | ALXN | 0.80% |
| Dicerna Pharmaceuticals | DRNA | 0.79% |
| Agios Pharmaceuticals | AGIO | 0.78% |
| Gilead Sciences | GILD | 0.78% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 22, 2021 | $0.04 | Mar 25, 2021 |
| Dec 21, 2020 | $0.176 | Dec 24, 2020 |
| Sep 21, 2020 | $0.089 | Sep 24, 2020 |
| Jun 22, 2020 | $0.017 | Jun 25, 2020 |
| Dec 20, 2019 | $0.001 | Dec 26, 2019 |
| Sep 20, 2019 | $0.003 | Sep 25, 2019 |
Biotechnology sector-related exchange traded funds could stumble in the near-term as increased regulatory scrutiny weighs on drugmakers. Among the hardest hit areas of Tuesday, the ALPS Medical Breakthr...
Biotech is ‘the superhero of the pandemic': investor
Antoine Papiernik, managing partner at Sofinnova Partners, joins Yahoo Finance to discuss trends in biotech and impacts the pandemic had on scientific discoveries.
Short-term investors may not see the long-term potential.
They've both already made some investors a lot of money over the last few years.
Stocks: Biotech and the outlook for vaccine stocks over the next 3-5 years
Yahoo Finance's Julie Hyman and Myles Udland spoke to Oppenheimer & Co. Analyst Hartaj Singh about the outlook for vaccine stocks.
Here we discuss a few ETFs that can enrich investors' portfolio in March amid a strong wave of optimism surrounding the coronavirus vaccine and introduction of another round of fiscal stimulus.
Investing in Biotech is a Long Game: Schulman
Feb.26 -- Polaris Partners Managing Partner Amy Schulman says that the key to investing in biotech is to diversify by investing in a portfolio. She cautions that biotech investments can be risky, but sa...
Biotech stocks offer a textbook retracement pattern. The risk is low, and the reward is high.
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
Biotech sector will continue to see activity: Margie Patel
Andy Kapyrin, Regent Atlantic director of research, and Margie Patel, Wells Fargo Asset Management senior portfolio manager and managing director, join CNBC's "The Exchange" to discuss the current infla...
The best biotech ETFs for Q2 2021 are ARKG, IDNA, and XBI.
Should investors watch for a squeeze?
After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded fun...
Biotech remains a strong opportunity for 2021, says Jefferies' Michael Yee
Michael Yee, Jefferies managing director, joins CNBC's "Closing Bell" to discuss the biotech sector's busy year, with companies such as Moderna racing to complete a Covid-19 vaccine and others looking f...
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
Stimulus deal appears to set the stage for the Santa rally in 2020.
Why this health-care strategist says the sector will rally into 2021
CNBC's Kelly Evans discusses the healthcare sector as well as biotech and pharma stocks and why the rally in these names can continue into 2021 with Jefferies' Jared Holz.
Both stock index ETFs and biotech stocks and ETFs have been on a tear lately thanks to promising coronavirus vaccine developments from several major pharmaceutical companies. But this week, the U.K. bec...
November has been a big month for stock and biotech ETFs, and with the Federal Aviation Administration announcing that it supported the “first mass air shipment” of coronavirus vaccines on Friday, pharm...
The biotech ETF hits a 52-week high on Nov 27. Can it soar further?
Biotech companies need capital, but challenge is finding high quality management teams: Cowen CEO
On Monday, Pfizer announced a successful phase 3 trial, showing the vaccine to be more than 90 percent effective. This comes as the FDA gave emergency use authorization to Eli Lilly's antibody treatment.
This biotech ETF has hit a new 52-week high. Are more gains in store?
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.
As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds, ...
How the presidential election could impact your portfolio
With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.
The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.
These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.
The race to introduce vaccine and treatment of coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
Buying 140 biotech stocks in one fell swoop could be a winning strategy.
Biotech Sector Chart The broad stock market’s two day rally saw biotech stocks surge higher. In particular, the reversal in Biotech Sector ETFs BBH and XBI looks to be bullish.
Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.
Justice Ruth Bader Ginsburg's death jeopardizes Obamacare's future, and that puts healthcare companies' revenue at risk.